Literature DB >> 31545230

FAM83H-AS1 is upregulated and predicts poor prognosis in colon cancer.

Lei Yang1, Jinpeng Cui2, Yakun Wang3, Jinjing Tan4.   

Abstract

Long noncoding RNAs (LncRNAs) have been proven to participate in many principal pathways during colonic mucosa tumourigenesis. FAM83H-AS1 has been identified as one of the LncRNAs that is dysregulated in multi-type cancers. Here, our purpose was to determine the expression pattern and clinical significance of FAM83H-AS1 and further analyse its prognostic value in colon cancer. FAM83H-AS1 expression was examined in 90 patients with colon cancer by RNAscope in situhybridization, and the expression levels were analysed with the overall survival (OS) rates for patients with colon cancer. TCGA datasets derived from colon cancer (COAD) were used to further validate the main findings. We demonstrated that the expression of FAM83H-AS1 was significantly higher in cancer tissues than in paired normal mucosa from colon cancer patients (P < 0.001). The prognostic analysis indicated that the OS rates for colon cancer patients with high levels of FAM83H-AS1 were significantly lower than those for patients with low levels of FAM83H-AS1 (P = 0.013). The higher levels of FAM83H-AS1 were found to be associated with a lower expression of SMAD1/5/9, which is involved in TGF-β signalling in colon cancer tissues (P = 0.0174). In HCT116 and SW480 cell lines, the down regulation of FAM83H-AS1 promoted the expression of SMAD1. Our investigations suggest that the upregulation of FAM83H-AS1 serves as a promising predictor and might be conducive for clinicians to estimate OS time. FAM83H-AS1 might serve as an inhibitor of TGF-β signalling.
Copyright © 2019 The Authors. Published by Elsevier Masson SAS.. All rights reserved.

Entities:  

Keywords:  Colon cancer; FAM83H-AS1; Long noncoding RNA; Prognosis

Year:  2019        PMID: 31545230     DOI: 10.1016/j.biopha.2019.109342

Source DB:  PubMed          Journal:  Biomed Pharmacother        ISSN: 0753-3322            Impact factor:   6.529


  7 in total

Review 1.  The clinical prognostic value of lncRNA FAM83H-AS1 in cancer patients: a meta-analysis.

Authors:  Qin Yang; Jie Wang; Pingyong Zhong; Tinggang Mou; Hao Hua; Pan Liu; Fei Xie
Journal:  Cancer Cell Int       Date:  2020-03-06       Impact factor: 5.722

2.  Long non-coding RNA FAM83H-AS1 acts as a potential oncogenic driver in human ovarian cancer.

Authors:  Xiaolei Yuan; Ying Huang; Man Guo; Xiaowei Hu; Peiling Li
Journal:  J Ovarian Res       Date:  2021-01-07       Impact factor: 4.234

3.  Overexpression of NNT-AS1 Activates TGF-β Signaling to Decrease Tumor CD4 Lymphocyte Infiltration in Hepatocellular Carcinoma.

Authors:  Yakun Wang; Lei Yang; Xichen Dong; Xin Yang; Xinxue Zhang; Zhe Liu; Xin Zhao; Tao Wen
Journal:  Biomed Res Int       Date:  2020-12-23       Impact factor: 3.411

Review 4.  Notch-associated lncRNAs profiling circuiting epigenetic modification in colorectal cancer.

Authors:  Omnia Emam; Eman F Wasfey; Nadia M Hamdy
Journal:  Cancer Cell Int       Date:  2022-10-13       Impact factor: 6.429

Review 5.  Long noncoding RNAs: functions and mechanisms in colon cancer.

Authors:  Sian Chen; Xian Shen
Journal:  Mol Cancer       Date:  2020-11-28       Impact factor: 27.401

6.  LncRNA FAM83H-AS1 maintains intervertebral disc tissue homeostasis and attenuates inflammation-related pain via promoting nucleus pulposus cell growth through miR-22-3p inhibition.

Authors:  Xin Jiang; Dong Chen
Journal:  Ann Transl Med       Date:  2020-11

7.  Significance of long non-coding RNA IFNG-AS1 in the progression and clinical prognosis in colon adenocarcinoma.

Authors:  Zhaoshun Wang; Zhongzheng Cao; Zhen Wang
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.